Caffeine Citrate

Comer, Alison M.; Perry, Caroline M.; Figgitt, David P.

doi:10.2165/00128072-200103010-00005

Cited by 107 publications

(27 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various references mention the gastrointestinal side effects of the methylxanthines, including feeding intolerance, aspirates, and gastrointestinal irritation presenting as bloody aspirates. 4,5,9,10 Apnoea also has been found to be associated with low birth weights below 1 000 g 11 and has been observed in as many as 80% of infants under 1 000 g. 12 Four patients (n = 31) developed apnoeic attacks during the study period.…”

Section: Gastrointestinal System Nutritional Supportmentioning

confidence: 97%

See 1 more Smart Citation

Caffeineversusaminophylline for the prevention of apnoea of prematurity in a teaching hospital in South Africa

Schellack

Gous

Mawela

2015

South African Family Practice

View full text Add to dashboard Cite

Study objectives:To determine the safety and efficacy of the use of oral anhydrous caffeine and intravenous aminophylline in the neonatal population using therapeutic drug levels and clinical effects as markers for determination. Design: Prospective randomised study. Patients: Thirty-one neonates admitted (aminophylline n = 16, caffeine n = 15) with a gestational age of less than or equal to 34 weeks for prevention of apnoea of prematurity (AOP) were enrolled. Results: Oral anhydrous caffeine or intravenous aminophylline were administered using prescribed study regimens. One peak level was taken for the two drugs on day 4 of treatment 2 hours after the maintenance dose was administered. The two regimens were clinically monitored using cardiovascular, respiratory, gastro-intestinal and central nervous system parameters four hourly. The two groups did not differ significantly for gestational age (p = 0.782), birth weight (p = 1), gender (p = 0.722), and Apgar scores determined at 5 minutes (p = 0.068). Serum concentrations were within range (5-20 μg/ml) for both study groups. The median pulse rate (beats per minute) for two days; day 7: 160 vs. 148 (p = 0.019); day 9: 168 vs. 147 (p = 0.020) and median respiratory rate (breaths per minute) for five days; day 3: 68 vs. 61 (p = 0.039); day 4: 67 vs. 57 (p = 0.014); day 5: 64 vs. 58 (p = 0.045); day 7: 65 vs. 50 (p = 0.021); day 8: 66 vs. 56 p = 0.014) were significantly higher in the aminophylline study arm. Conclusion:The findings of the study indicated that caffeine is an effective alternative for intravenous aminophylline in prevention of AOP. The oral administration of caffeine may also have an advantage in a resource-poor setting.

show abstract

Section: Gastrointestinal System Nutritional Supportmentioning

confidence: 97%

“…Intravenous access was also problematic in many neonates who were admitted only for kangaroo mother care (KMC). Caffeine occurs naturally in many plants and has been used for over 20 years to treat apnoea of prematurity 5 and may be a suitable alternative.…”

Section: Introductionmentioning

confidence: 99%

Caffeineversusaminophylline for the prevention of apnoea of prematurity in a teaching hospital in South Africa

Schellack

Gous

Mawela

2015

South African Family Practice

View full text Add to dashboard Cite

show abstract

“…9 The in vivo translation of these findings in preterm infants is still unknown. Although caffeine citrate has a wide therapeutic index for the treatment of apnea of prematurity and no routine serum levels are recommended, 11-13 factors such as the empiric dose adjustment on the basis of clinical response and the variations in renal clearance caused by acute clinical events could lead to serum caffeine levels outside of the recommended therapeutic levels, potentially changing the pattern of binding to ARs. 14-17 …”

mentioning

confidence: 99%

Correlation between Serum Caffeine Levels and Changes in Cytokine Profile in a Cohort of Preterm Infants

Chavez‐Valdez

Ahlawat

Wills‐Karp

et al. 2011

The Journal of Pediatrics

View full text Add to dashboard Cite

Objective To determine changes in cytokine levels associated with caffeine treatment in a cohort of preterm infants. Study design For this observational prospective study, we collected clinical data from 26 preterm infants (≤30 weeks gestational age). In addition to caffeine levels, cytokine profiles in peripheral blood (PB) and tracheal aspirates (TA) were determined with enzyme-linked immunosorbent assay at birth, before and after (at 24 hours and 1 week) initiation of caffeine. Non-parametric statistics were applied. Results Included infants were 26.9 1.7 weeks gestational age and weighed 985 ± 202 g. At birth, all cytokine concentrations were significantly greater in TA than PB. Serum caffeine levels were 11.1 μg/mL (interquartile range, 1.85) at approximately 24 hours post-load and 16.4 (8.7) μg/mL at 1 week on treatment. At approximately 24 hours post-load, interleukin (IL)-10 levels decreased by 47.5% (P = .01) in PB and 38.5% (P = .03) in TA, whereas other cytokine levels remained unchanged. At 1 week, caffeine levels were correlated (U-shaped) with changes in proinflammatory tumor necrosis factor-α (R2 = 0.65; P = .0008), interleukin (IL)-1β (R2 = 0.73; P = .0007), and IL-6 (R2 = 0.59; P = .003), whereas inversely correlated (linear) with the anti-inflammatory IL-10 (R2 = 0.64; P = .0008). Altogether, caffeine, at serum levels ≥20 μg/mL, was associated with a proinflammatory profile after 1 week of treatment. Conclusions Caffeine treatment for apnea of prematurity correlates with changes in cytokine profile. Caffeine levels ≥20 μg/mL are associated with a proinflammatory profile in our cohort of preterm infants.

show abstract

“…Caffeine citrate is a central nervous stimulant and helps to restore alertness. Pharmaceutically, caffeine citrate is used in the treatment of apnea in newborns; also it is the component of many of the analgesic formulations, where it demonstrates a synergistic effect with those analgesics (Comer et al, 2001; Sawynok, 1995). …”

Section: Introductionmentioning

confidence: 99%

Development of taste masked caffeine citrate formulations utilizing hot melt extrusion technology and in vitro–in vivo evaluations

Pimparade

Morott

Park

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

The objective of this study was to develop caffeine citrate orally disintegrating tablet (ODT) formulations utilizing hot-melt extrusion technology and evaluate the ability of the formulation composition to mask the unpleasant bitter taste of the drug using in vitro and in vivo methods. Ethylcellulose, along with a suitable plasticizer, was used as a polymeric carrier. Pore forming agents were incorporated into the extruded matrix to enhance drug release. A modified screw configuration was applied to improve the extrusion processability and to preserve the crystallinity of the API. The milled extrudates were subjected to dissolution testing in an artificial salivary fluid and investigations using e-tongue, to assess the extent of masking of bitter taste of the API. There was an insignificant amount of drug released from the formulation in the salivary medium while over 80% of drug released within 30 min in 0.1 N HCl. ODTs were also developed with the extrudate mixed with mannitol and crospovidone. The quality properties such as friability and disintegration time of the ODTs met the USP specifications. The lead extrudate formulations and the ODTs prepared using this formulation were subjected to human gustatory evaluation. The formulations were found to mask the unpleasant taste of caffeine citrate significantly.

show abstract

Caffeine Citrate

Cited by 107 publications

References 73 publications

Caffeineversusaminophylline for the prevention of apnoea of prematurity in a teaching hospital in South Africa

Caffeineversusaminophylline for the prevention of apnoea of prematurity in a teaching hospital in South Africa

Correlation between Serum Caffeine Levels and Changes in Cytokine Profile in a Cohort of Preterm Infants

Development of taste masked caffeine citrate formulations utilizing hot melt extrusion technology and in vitro–in vivo evaluations

Contact Info

Product

Resources

About